Program
diacerein
Also written as “Diacerein”, “diacerein 1% ointment” and “AC-201”.
Its studies are mostly in Osteoarthritis, Knee · Epidermolysis Bullosa Simplex · Epidermolysis Bullosa · Psoriasis · Gout, led by 7 companies.
Drug pageDiacerein: every studyMany companies study it; this page follows only the 21 they lead. All 37 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Castle Creek Pharmaceuticalsits history only | 70 open or running | phase 2since May 10, 2017 | May 10, 2017 | none ahead |
| TWi Biotechnologyits history only | 61 open or running | phase 3since Sep 12, 2023 | Jan 11, 2011 | none ahead |
| Wockhardtits history only | 30 open or running | phase 4since Feb 26, 2007 | Feb 26, 2007 | none ahead |
| TRB Chemedicaits history only | 21 open or running | phase 3since Mar 16, 2020 | Jun 28, 2010 | Dec 31, 2026phase 3 · NCT04318041 |
| Accro Bioscience (Suzhou)its history only | 10 open or running | phase 2since May 7, 2025 | May 7, 2025 | none ahead |
| ANS Pharmaits history only | 10 open or running | phase 2since Jun 27, 2017 | Jun 27, 2017 | none ahead |
| TRB Chemedica International | 10 open or running | phase 3since Feb 10, 2016 | Feb 10, 2016 | none ahead |
Also a collaborator on its studies: ArthroLab and TKL Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of TRB Chemedica International only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 10, 2016First study: phase 3 study in OsteoarthritisFirst studyNCT02688400 · 380 enrolled · Austria, Belgium, Canada and more
TargetBeta
“AC-203 (diacerein 1% ointment) is a topical formulation of diacerein, well-known for its ability to inhibit IL-1β and other proinflammatory cytokines.”study text, by rule · the study
Other programs on IL1B
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lutikizumab | AbbVie | phase 3 | 12 |
| arumakimig | Novartis | phase 2 | 7 |
| ABBV-1451 | AbbVie | phase 1 | 1 |
Studies
The one study TRB Chemedica International leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02688400Osteoarthritis · Austria, Belgium, Canada and more | 3 | Completed | Jun 26, 2018 | 380 |
How it is read
Names in the registry
- “Diacerein”, 4 entries
- “diacerein 1% ointment”, 4 entries
- “AC-201”, 3 entries
- “AC-203”, 2 entries
- “Diacerein 1% ointment”, 2 entries
Conditions, from the studies’ own filings
- Osteoarthritis, Knee, 3 studies
- Epidermolysis Bullosa Simplex, 3 studies
- Epidermolysis Bullosa, 2 studies
- Psoriasis, 1 study
- Gout, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.